Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
Crispr Therapeutics AG (CRSP) Stock Price & Analysis
7,578 Followers
CRSP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$37.55 - $91.10
Previous Close$53.81
Volume1.00M
Average Volume (3M)1.72M
Market Cap
$4.57B
Enterprise Value$3.11B
Total Cash (Recent Filing)$1.69B
Total Debt (Recent Filing)$238.63M
Price to Earnings (P/E)-27.3
Beta1.15
Next Earnings
Jul 29, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding80,275,950
10 Day Avg. Volume1,320,201
30 Day Avg. Volume1,722,324
Standard Deviation0.20
R-Squared0.22
Alpha0.00405
Financial Highlights & Ratios
Price to Book (P/B)2.26
Price to Sales (P/S)21.47
Price to Cash Flow (P/CF)-11.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.38
Enterprise Value/Gross Profit8.38
Enterprise Value/Ebitda-23.78
Forecast
1Y Price Target
$81.00Price Target Upside47.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Crispr Therapeutics AG News
PremiumStock Analysis & Ideas
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
Bulls Say, Bears Say
Bulls Say
Financial HealthPro-forma cash and equivalents are greater than $2.1 billion, indicating a strong financial position for CRSP.
Market PotentialThe CTX320 trial for anti-Lp(a) has the potential to drive significant upside in a market estimated to be around $20B+.
Product ApprovalLyfgenia (lovo-cel) was approved for sickle cell disease (SCD), which could represent a multi-billion dollar opportunity in the US alone.
Bears Say
Financial PerformanceNo revenues recognized for Casgevy sales in 4Q:23 reporting.
Market SentimentAnalyst downgrades to Underperform with a $30 price target as CRSP shares appear overvalued based on the Casgevy launch.
Stock DilutionCRSP announced a $280 million registered direct offering at $71.50/share, which could potentially dilute existing shareholders' value.
---
Ownership Overview
23.58% Insiders
17.06% Mutual Funds
33.79% Other Institutional Investors
25.57% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRSP FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $37.55 and its highest was $91.10 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Currently, no data Available
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is Jul 29, 2024 which is in 86 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on Apr 30, 2024. The company reported -$1.555 earnings per share for the quarter, missing the consensus estimate of -$1.354 by -$0.201.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 84,883,095 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$1.555 in its last earnings report, missing expectations of -$1.354. Following the earnings report the stock price went down -3.356%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 534M.
---
Crispr Therapeutics AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$81.00 (47.09% Upside)
$81.00 (47.09% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 96%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.63%
12-Months-Change
Fundamentals
Return on Equity
-8.17%
Trailing 12-Months
Asset Growth
-0.60%
Trailing 12-Months
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
---
CRSP Stock 12 Months Forecast
Average Price Target
$81.00
▲(47.09% Upside)
Technical Analysis
Best Analysts Covering CRSP
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+22.88%
reiterated a buy rating 11 months ago
Copying Anthony Butler's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +22.88% per trade.
---